Wang Man, Zhu Lijie, Yang Xiaoxu, Li Jiahui, Liu Yu'e, Tang Ying
Department of Respiratory Medicine, The First Hospital of Jilin University, Changchun, Jilin, China.
Tongji University Cancer Center, Shanghai Tenth People's Hospital of Tongji University, School of Medicine, Tongji University, Shanghai, China.
Front Pharmacol. 2023 Feb 15;14:1132158. doi: 10.3389/fphar.2023.1132158. eCollection 2023.
Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune checkpoint inhibitors (ICIs) therapy. Unfortunately, cancer patients acquire adaptive immune resistance, leading to poor prognosis. Tumor microenvironment (TME) has been demonstrated to play a critical role in participating in acquired adaptive immune resistance. TME is associated with molecular heterogeneity of immunotherapy efficacy in lung cancer. In this article, we discuss how immune cell types of TME are correlated with immunotherapy in lung cancer. Moreover, we describe the efficacy of immunotherapy in driven gene mutations in lung cancer, including KRAS, TP53, EGFR, ALK, ROS1, KEAP1, ZFHX3, PTCH1, PAK7, UBE3A, TNF-α, NOTCH, LRP1B, FBXW7, and STK11. We also emphasize that modulation of immune cell types of TME could be a promising strategy for improving adaptive immune resistance in lung cancer.
肺癌是死亡率最高的常见恶性肿瘤。肺癌患者已从免疫疗法中获益，包括免疫检查点抑制剂（ICI）疗法。不幸的是，癌症患者会产生适应性免疫抗性，导致预后不良。肿瘤微环境（TME）已被证明在参与获得性适应性免疫抗性中起关键作用。TME与肺癌免疫治疗疗效的分子异质性相关。在本文中，我们讨论了TME的免疫细胞类型如何与肺癌免疫治疗相关。此外，我们描述了免疫治疗在肺癌驱动基因突变中的疗效，这些驱动基因突变包括KRAS、TP53、EGFR、ALK、ROS1、KEAP1、ZFHX3、PTCH1、PAK7、UBE3A、TNF-α、NOTCH、LRP1B、FBXW7和STK11。我们还强调，调节TME的免疫细胞类型可能是改善肺癌适应性免疫抗性的一种有前景的策略。
